Linked Life Data

20968143

Source:http://linkedlifedata.com/resource/pubmed/id/20968143

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20968143rdf:typepubmed:Citationlld:pubmed
pubmed-article:20968143lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:20968143lifeskim:mentionsumls-concept:C0376358lld:lifeskim
pubmed-article:20968143lifeskim:mentionsumls-concept:C0014921lld:lifeskim
pubmed-article:20968143lifeskim:mentionsumls-concept:C0600688lld:lifeskim
pubmed-article:20968143lifeskim:mentionsumls-concept:C0205276lld:lifeskim
pubmed-article:20968143lifeskim:mentionsumls-concept:C1979963lld:lifeskim
pubmed-article:20968143lifeskim:mentionsumls-concept:C2587213lld:lifeskim
pubmed-article:20968143lifeskim:mentionsumls-concept:C1831735lld:lifeskim
pubmed-article:20968143lifeskim:mentionsumls-concept:C2003903lld:lifeskim
pubmed-article:20968143lifeskim:mentionsumls-concept:C0439231lld:lifeskim
pubmed-article:20968143pubmed:issue4lld:pubmed
pubmed-article:20968143pubmed:dateCreated2010-10-25lld:pubmed
pubmed-article:20968143pubmed:abstractText[11C]choline positron emission tomograhy can be useful to detect metastatic disease and to localize isolated lymph node relapse after primary treatment in case of prostate-specific antigen failure. In case of lymph node failure in prostate cancer patients, surgery or radiotherapy can be proposed with a curative intent. Some reports have suggested that radiotherapy could have a role in local control of oligometastatic lymph node disease. This is the first reported case of [11C]choline positron emission tomography-guided helical tomotherapy concomitant with estramustine for the treatment of pelvic-recurrent prostate cancer. At 24 months after the end of helical tomotherapy, prostate-specific antigen was undetectable and no late toxicities were recorded. A disease-free survival of 24 months, in the absence of any type of systemic therapy, is uncommon in metastatic prostate cancer. The therapeutic approach of the case report is discussed and a literature review on the issue is presented.lld:pubmed
pubmed-article:20968143pubmed:languageenglld:pubmed
pubmed-article:20968143pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20968143pubmed:citationSubsetIMlld:pubmed
pubmed-article:20968143pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20968143pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20968143pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20968143pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20968143pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20968143pubmed:statusMEDLINElld:pubmed
pubmed-article:20968143pubmed:issn0300-8916lld:pubmed
pubmed-article:20968143pubmed:authorpubmed-author:MessaCristina...lld:pubmed
pubmed-article:20968143pubmed:authorpubmed-author:RossoAlbertoAlld:pubmed
pubmed-article:20968143pubmed:authorpubmed-author:FiorinoClaudi...lld:pubmed
pubmed-article:20968143pubmed:authorpubmed-author:GianolliLuigi...lld:pubmed
pubmed-article:20968143pubmed:authorpubmed-author:PicchioMariaMlld:pubmed
pubmed-article:20968143pubmed:authorpubmed-author:CozzariniCesa...lld:pubmed
pubmed-article:20968143pubmed:authorpubmed-author:SchipaniStefa...lld:pubmed
pubmed-article:20968143pubmed:authorpubmed-author:GajateAna...lld:pubmed
pubmed-article:20968143pubmed:authorpubmed-author:Di...lld:pubmed
pubmed-article:20968143pubmed:authorpubmed-author:AlongiFilippo...lld:pubmed
pubmed-article:20968143pubmed:authorpubmed-author:AlongiPierpao...lld:pubmed
pubmed-article:20968143pubmed:issnTypePrintlld:pubmed
pubmed-article:20968143pubmed:volume96lld:pubmed
pubmed-article:20968143pubmed:ownerNLMlld:pubmed
pubmed-article:20968143pubmed:authorsCompleteYlld:pubmed
pubmed-article:20968143pubmed:pagination613-7lld:pubmed
pubmed-article:20968143pubmed:meshHeadingpubmed-meshheading:20968143...lld:pubmed
pubmed-article:20968143pubmed:meshHeadingpubmed-meshheading:20968143...lld:pubmed
pubmed-article:20968143pubmed:meshHeadingpubmed-meshheading:20968143...lld:pubmed
pubmed-article:20968143pubmed:meshHeadingpubmed-meshheading:20968143...lld:pubmed
pubmed-article:20968143pubmed:meshHeadingpubmed-meshheading:20968143...lld:pubmed
pubmed-article:20968143pubmed:meshHeadingpubmed-meshheading:20968143...lld:pubmed
pubmed-article:20968143pubmed:meshHeadingpubmed-meshheading:20968143...lld:pubmed
pubmed-article:20968143pubmed:meshHeadingpubmed-meshheading:20968143...lld:pubmed
pubmed-article:20968143pubmed:meshHeadingpubmed-meshheading:20968143...lld:pubmed
pubmed-article:20968143pubmed:meshHeadingpubmed-meshheading:20968143...lld:pubmed
pubmed-article:20968143pubmed:meshHeadingpubmed-meshheading:20968143...lld:pubmed
pubmed-article:20968143pubmed:meshHeadingpubmed-meshheading:20968143...lld:pubmed
pubmed-article:20968143pubmed:meshHeadingpubmed-meshheading:20968143...lld:pubmed
pubmed-article:20968143pubmed:meshHeadingpubmed-meshheading:20968143...lld:pubmed
pubmed-article:20968143pubmed:meshHeadingpubmed-meshheading:20968143...lld:pubmed
pubmed-article:20968143pubmed:meshHeadingpubmed-meshheading:20968143...lld:pubmed
pubmed-article:20968143pubmed:articleTitle[11C]choline-PET-guided helical tomotherapy and estramustine in a patient with pelvic-recurrent prostate cancer: local control and toxicity profile after 24 months.lld:pubmed
pubmed-article:20968143pubmed:affiliationRadiotherapy Department, San Raffaele Scientific Institute, Milan, Italy. filippoalongi@libero.itlld:pubmed
pubmed-article:20968143pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20968143pubmed:publicationTypeCase Reportslld:pubmed